{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T14:01:52Z","timestamp":1780236112098,"version":"3.54.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.7759\/cureus.109965","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T13:30:58Z","timestamp":1780234258000},"source":"Crossref","is-referenced-by-count":0,"title":["CD20-Negative Primary Intestinal Diffuse Large B-cell Lymphoma With TP53 Mutation in Poorly Controlled Celiac Disease: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Chaimae","family":"Bekhakh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anass","family":"Haloui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassira","family":"Karich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.79","article-title":"ACG clinical guidelines: diagnosis and management of celiac disease","volume":"108","author":"Rubio-Tapia A","year":"2013","unstructured":"Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013, 108:656-76; quiz 677. 10.1038\/ajg.2013.79","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.02.027","article-title":"Association of celiac disease and intestinal lymphomas and other cancers","volume":"128","author":"Catassi C","year":"2005","unstructured":"Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology. 2005, 128:S79-86. 10.1053\/j.gastro.2005.02.027","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.032094","article-title":"Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma","volume":"54","author":"Smedby KE","year":"2005","unstructured":"Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut. 2005, 54:54-9. 10.1136\/gut.2003.032094","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie J","year":"2011","unstructured":"Delabie J, Holte H, Vose JM, et al.. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011, 118:148-55. 10.1182\/blood-2011-02-335216","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03682-3","article-title":"Malignant complications of celiac disease: a case series and review of the literature","volume":"16","author":"Packova B","year":"2022","unstructured":"Packova B, Kohout P, Dastych M, Prokesova J, Grolich T, Kroupa R. Malignant complications of celiac disease: a case series and review of the literature. J Med Case Rep. 2022, 16:460. 10.1186\/s13256-022-03682-3","journal-title":"J Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette ZY","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, et al.. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012, 120:3986-96. 10.1182\/blood-2012-05-433334","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01612.x","article-title":"Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)","volume":"68","author":"Rossmann ED","year":"2002","unstructured":"Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol. 2002, 68:299-306. 10.1034\/j.1600-0609.2002.01612.x","journal-title":"Eur J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2009.11.002","article-title":"Enteropathy associated T-cell lymphoma and its precursor lesions","volume":"24","author":"van de Water JM","year":"2010","unstructured":"van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol. 2010, 24:43-56. 10.1016\/j.bpg.2009.11.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.06.006","article-title":"Celiac disease: an immunological jigsaw","volume":"36","author":"Meresse B","year":"2012","unstructured":"Meresse B, Malamut G, Cerf-Bensussan N. Celiac disease: an immunological jigsaw. Immunity. 2012, 36:907-19. 10.1016\/j.immuni.2012.06.006","journal-title":"Immunity"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)01047-3","article-title":"Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease","volume":"125","author":"Mention JJ","year":"2003","unstructured":"Mention JJ, Ben Ahmed M, B\u00e8gue B, et al.. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003, 125:730-45. 10.1016\/s0016-5085(03)01047-3","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.069","article-title":"Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II","volume":"136","author":"Malamut G","year":"2009","unstructured":"Malamut G, Afchain P, Verkarre V, et al.. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009, 136:81-90. 10.1053\/j.gastro.2008.09.069","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1454","article-title":"Pax5: the guardian of B cell identity and function","volume":"8","author":"Cobaleda C","year":"2007","unstructured":"Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007, 8:463-70. 10.1038\/ni1454","journal-title":"Nat Immunol"},{"key":"ref13","article-title":"Expression of perforin in nasal lymphoma. Additional evidence of its natural killer cell derivation","volume":"149","author":"Mori N","year":"1996","unstructured":"Mori N, Yatabe Y, Oka K, Kinoshita T, Kobayashi T, Ono T, Asai J. Expression of perforin in nasal lymphoma. Additional evidence of its natural killer cell derivation. Am J Pathol. 1996, 149:699-705.","journal-title":"Am J Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn LH","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021, 384:842-58. 10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi PF","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, et al.. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021, 22:790-800. 10.1016\/S1470-2045(21)00139-X","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal S","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, et al.. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017, 377:111-21. 10.1056\/NEJMoa1701719","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/496414-cd20-negative-primary-intestinal-diffuse-large-b-cell-lymphoma-with-tp53-mutation-in-poorly-controlled-celiac-disease-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T13:30:59Z","timestamp":1780234259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/496414-cd20-negative-primary-intestinal-diffuse-large-b-cell-lymphoma-with-tp53-mutation-in-poorly-controlled-celiac-disease-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.109965","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}